Mounjaro®
Starting from £179.99/mo
Start journey Learn moreFeeling lightheaded when you stand up after starting Mounjaro is more common than most people expect. Orthostatic hypotension — a drop in blood pressure on rising — has been reported by people using tirzepatide, and it is something prescribers actively look out for. It is not listed as a common adverse effect in the Mounjaro SmPC, but the mechanism behind it is well understood, and for most people it is manageable rather than serious. Mounjaro (tirzepatide) is a prescription-only medicine: a prescriber assesses whether it is appropriate for you individually, and any symptoms like this should be discussed with your clinical team rather than managed alone.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Orthostatic hypotension happens when your cardiovascular system does not compensate quickly enough for the shift in blood distribution that occurs the moment you go from lying or sitting to standing. Normally, your autonomic nervous system fires off a rapid response (constricting vessels, nudging heart rate up) to keep pressure stable. Tirzepatide can blunt that response for a few reasons.
First, the medicine's GLP-1 receptor activity produces mild vasodilation in some people, making vessels slightly more relaxed than usual. Second, and probably more significant in practice: reduced appetite and nausea during dose titration means many people eat and drink less than they normally would. A lower circulating fluid volume leaves less buffer when gravity pulls blood toward your legs. Third, tirzepatide slows gastric emptying, which can amplify post-meal blood pressure dips (a phenomenon called postprandial hypotension) that then compound any orthostatic effect.
None of this means the medicine is doing something wrong. It means the body is adapting, and that adaptation takes a few weeks. The NHS tirzepatide patient page lists dizziness among reported effects, and the Mounjaro SmPC notes blood pressure monitoring as part of appropriate clinical oversight. If you want a closer look at how tirzepatide affects blood pressure and contributes to hypotension, that covers the mechanisms in more detail. If dizziness is happening every time you stand, that is worth reporting to your prescriber rather than waiting it out.
Not everyone notices it. People who start from a higher baseline blood pressure, or who are already taking antihypertensive medicines, are more likely to experience a meaningful drop when they stand. There is a reasonable physiological logic to this: if your vessels are already pharmacologically relaxed, adding another vasodilatory influence shifts the system closer to symptomatic territory.
Older adults tend to have less reserve in their autonomic reflexes, which makes the compensatory response slower. Anyone prone to dehydration (from vomiting or diarrhoea during the early GI side effects that tirzepatide commonly brings) is also more vulnerable. People taking diuretics, ACE inhibitors, ARBs, or calcium channel blockers alongside Mounjaro should make sure their prescriber knows, so blood pressure monitoring can be planned appropriately. The interaction between tirzepatide and cardiovascular medicines is one of the things covered in a thorough pre-treatment consultation; you can read more about how Mounjaro interacts with statins and other concurrent medicines if that is relevant to your situation.
A lower starting blood pressure is not automatically protective, thin people with a naturally low reading can also feel faint on standing if fluid intake drops. The key variable is usually hydration, not starting BMI.
The single most effective thing is pacing your transitions. Sit on the edge of the bed for twenty seconds before you stand. Do the same from a chair. It sounds almost too simple, but it gives the baroreceptors time to signal the heart before you are already upright. Most people adopt this without thinking about it after the first couple of dizzy moments.
Hydration is the other lever you can pull. Aim for roughly 1.5 to 2 litres of fluid through the day, not all at once, and not with caffeine as the primary source. If nausea is making that hard, small, frequent sips work better than trying to gulp a glass. The nausea usually eases within the first two weeks of a new dose; the dizziness often follows the same pattern.
Compression stockings help some people, particularly those on antihypertensives. They prevent the pooling of blood in the legs that triggers the drop. Worth a conversation with your GP or pharmacist if episodes are frequent. Reducing salt is often good general advice for blood pressure, but during dose titration when the issue is low rather than high pressure, very aggressive salt restriction can work against you, another reason to discuss symptoms rather than self-adjust.
If you would like context on how tirzepatide affects blood pressure more broadly, the detail on whether Mounjaro raises or lowers blood pressure covers the wider picture. And for anyone considering treatment, understanding how Mounjaro compares to hypoglycaemia risks helps separate different types of light-headedness that can feel similar but have distinct causes.
Mild, brief dizziness on standing (lasting a few seconds and resolving once you are upright and still) is not an emergency. Frequent episodes, loss of consciousness or near-fainting, or dizziness that does not settle after two or three weeks at a stable dose are all worth reporting promptly. A prescriber may want to check your lying and standing blood pressure, review whether a concurrent antihypertensive needs adjusting, or consider whether your current Mounjaro dose is the right one for now.
Chest pain, extreme weakness, or confusion alongside dizziness mean you should call 999 or go to A&E rather than wait for a callback. These are not typical presentations of orthostatic hypotension from tirzepatide, but they are signs that something else needs ruling out urgently.
Suspected side effects from Mounjaro can also be reported directly through the MHRA Yellow Card scheme, a step the NHS actively encourages, especially given that tirzepatide carries a Black Triangle (▼) status meaning it is under enhanced monitoring. Reporting contributes to a broader safety picture that benefits everyone on the medicine. If you're unsure whether what you are experiencing is within the expected range, our prescribers review clinical queries seven days a week: contact the team here.
Before stepping into any treatment, it helps to have the full picture. The tirzepatide overview covers how the medicine works, what the evidence says, and what a clinical consultation at a GPhC-registered pharmacy like ours involves. If you are preparing your medication, our guide on how to mix tirzepatide with bacteriostatic water walks you through the process step by step.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.